The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Pierre Fabre
Research Funding - Bristol Myers Squibb Foundation (Inst); Merck Sharp & Dohme (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Merck Sharp & Dohme
Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase 3 trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma.
 
Alexander M. Eggermont
Stock and Other Ownership Interests - RiverD; Skyline Diagnostics
Honoraria - BIOCAD; BIOINVENT; BioNTech; CatalYm; Ellipses Pharma; GlaxoSmithKline; IO Biotech; ISA Pharmaceuticals; MSD; NEKTAR; Novartis; Pfizer; Sellas Life Sciences; Skyline Diagnostics
Consulting or Advisory Role - BIOINVENT; CatalYm; Ellipses Pharma; GlaxoSmithKline; IO BIOTECH; ISA Pharmaceuticals; MSD; NEKTAR; Novartis; Pfizer; Sellas Life Sciences; Skyline Diagnostics
Speakers' Bureau - BIOCAD; BMSi; MSD
 
Andrey Meshcheryakov
Honoraria - Amgen; AstraZeneca; Bayer; BioCad; Bristol-Myers Squibb; Eisai; Lilly; Merck; Sanofi/Aventis; SERVIER; Takeda
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; BioCad; Bristol-Myers Squibb; Eisai; Lilly; Merck; Sanofi/Aventis; Sanofi/Aventis; SERVIER; Takeda
Research Funding - AstraZeneca; Sanofi
Travel, Accommodations, Expenses - BioCad; Merck; Merck Sharp & Dohme; Sanofi; SERVIER
 
Victoria Atkinson
Honoraria - Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Nektar; Novartis; Pierre Fabre; Roche/Genentech
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Pierre Fabre; QBiotics; Roche
Speakers' Bureau - Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Roche/Genentech
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Sharp & Dohme; OncoSec; Pierre Fabre
 
Christian U. Blank
Stock and Other Ownership Interests - Immagene; Uniti Cars
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); GenMab (Inst); GlaxoSmithKline (Inst); Lilly (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche/Genentech (Inst); Third Rock Ventures
Research Funding - Bristol-Myers Squibb (Inst); NanoString Technologies (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Mario Mandalà
Honoraria - MSD Oncology; Novartis; Pierre Fabre
Consulting or Advisory Role - Bristol-Myers Squibb; MSD Oncology; Novartis; Pierre Fabre
Research Funding - Novartis (Inst)
 
Georgina V. Long
Consulting or Advisory Role - Aduro Biotech; Amgen; Array BioPharma; Boehringer Ingelheim; Bristol-Myers Squibb; Hexal; Highlight Therapeutics; Merck Sharpe & Dohme; Novartis; OncoSec; Pierre Fabre; QBiotics; Regeneron; Skyline Diagnostics; Specialised Therapeutics
 
Catherine Barrow
No Relationships to Disclose
 
Anna Maria Di Giacomo
Consulting or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; Merck Sharp & Dohme; Novartis; Pierre Fabre; Sanofi Aventis GmbH
 
Rosalie Stephens
No Relationships to Disclose
 
Shahneen Kaur Sandhu
Honoraria - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Merck Serono (Inst)
Consulting or Advisory Role - Amgen
Speakers' Bureau - Bristol-Myers Squibb; Merck; Roche/Genentech
Research Funding - Amgen (Inst); AstraZeneca (Inst); Endocyte/Advanced Accelerator Applications (Inst); Genentech/Roche (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Roche/Genentech
 
Ragini Reiney Kudchadkar
Honoraria - Array BioPharma; Bristol-Myers Squibb
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; Immunocore; Merck; Novartis; Regeneron
Research Funding - Merck (Inst); Regeneron (Inst)
 
Pablo L. Ortiz-Romero
Consulting or Advisory Role - 4SC; Helsinn Healthcare; Innate Pharma; Kyowa Kirin; miRagen; Ricordati Rare Disease; Takeda
Expert Testimony - Helsinn Healthcare; Kyowa Kirin; Ricordati Rare Disease; Takeda
 
Inge Marie Svane
No Relationships to Disclose
 
Alexander Christopher Jonathan Van Akkooi
Consulting or Advisory Role - 4SC (Inst); Amgen (Inst); Bristol-Myers Squibb (Inst); Merck/Pfizer (Inst); MSD Oncology (Inst); Novartis (Inst); Pierre Fabre (Inst); Sanofi (Inst); Sirius Medical (Inst)
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Merck/Pfizer (Inst)
Travel, Accommodations, Expenses - Novartis
 
Clemens Krepler
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Nageatte Ibrahim
Employment - Merck
Stock and Other Ownership Interests - GlaxoSmithKline; Merck
 
Sandrine Marreaud
No Relationships to Disclose
 
Michal Kicinski
Research Funding - BMS (Inst); Janssen (Inst); Merck (Inst); Pierre Fabre (Inst)
 
Stefan Suciu
Research Funding - Bristol-Myers Squibb (Inst); Merck (Inst)
 
Caroline Robert
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi